<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726958</url>
  </required_header>
  <id_info>
    <org_study_id>EI/2014/141</org_study_id>
    <nct_id>NCT02726958</nct_id>
  </id_info>
  <brief_title>Early Postoperative Blood Glucose Variability and Outcome After TAVI</brief_title>
  <acronym>GLYTAVI</acronym>
  <official_title>Early Postoperative Blood Glucose Variability and Outcome After TAVI : a Retrospective Single-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress hyperglycaemia is a well-known risk factor of postoperative morbidity and mortality in
      cardiac surgery. Recently, several authors have reported that increased blood glucose (BG)
      variability could worsen the prognosis in this population.The transcatheter aortic valve
      implantation (TAVI) is a low invasive procedure proposed as an alternative technique to
      aortic valve replacement surgery in high-risk patients.

      The aim of this study is to describe the incidence of stress hyperglycaemia and assess
      whether BG variability could impact the outcome of patients undergoing TAVI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of stress hyperglycemia</measure>
    <time_frame>48 hours</time_frame>
    <description>Stress hyperglycemia is defined as a blood glucose value above 7.7 mmol/l requiring insulin infusion within the 48 first hours following the TAVI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose value</measure>
    <time_frame>48 hours</time_frame>
    <description>Mean blood glucose value is the mean of all the blood glucose values measured during the 48 first hours following the TAVI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of blood glucose value</measure>
    <time_frame>48 hours</time_frame>
    <description>Standard deviation of glucose value is the standard deviation of all the blood glucose values measured during the 48 first hours following the TAVI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate hypoglycemia</measure>
    <time_frame>48 hours</time_frame>
    <description>Moderate hypoglycemia is defined as a blood glucose value under 3.3 mmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycemia</measure>
    <time_frame>48 hours</time_frame>
    <description>Severe hypoglycemia is defined as a blood glucose value under 2.2 mmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hyperglycemia</measure>
    <time_frame>48 hours</time_frame>
    <description>Severe hyperglycemia is defined as a blood glucose value above 11.0 mmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variability of blood glucose</measure>
    <time_frame>48 hours</time_frame>
    <description>The coefficient of variability is the ratio of the standard deviation on the mean blood glucose value, expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily variation of blood glucose</measure>
    <time_frame>48 hours</time_frame>
    <description>The mean daily variation of blood glucose is defined as the mean of the daily differences between the maximal and the minimal glucose value.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">160</enrollment>
  <condition>Stress Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>group M</arm_group_label>
    <description>patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group T</arm_group_label>
    <description>other patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Planned transcatheter aortic valve implantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years old

          -  severe degenerative symptomatic aortic stenosis

          -  logistic Euroscore ≥ 20% or/and Society of Thoracic Surgeons score (STS) ≥ 10%

          -  recused for a conventional valve replacement by multidisciplinary team (surgeon,
             cardiologist) because of surgical contraindication or comorbidities related to the
             patient.

          -  written consent before the procedure concerning anonymous data processing.

        Exclusion Criteria:

          -  death per procedure

          -  postoperative admission in a critical care unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie DEPIERRE</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Régional Universitaire de Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Jean Minjoz Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Goldberg PA, Sakharova OV, Barrett PW, Falko LN, Roussel MG, Bak L, Blake-Holmes D, Marieb NJ, Inzucchi SE. Improving glycemic control in the cardiothoracic intensive care unit: clinical experience in two hospital settings. J Cardiothorac Vasc Anesth. 2004 Dec;18(6):690-7.</citation>
    <PMID>15650975</PMID>
  </reference>
  <reference>
    <citation>Meyfroidt G, Keenan DM, Wang X, Wouters PJ, Veldhuis JD, Van den Berghe G. Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. Crit Care Med. 2010 Apr;38(4):1021-9. doi: 10.1097/CCM.0b013e3181cf710e.</citation>
    <PMID>20124887</PMID>
  </reference>
  <reference>
    <citation>Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris JM Jr, May AK. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg. 2008 Aug;74(8):679-85; discussion 685.</citation>
    <PMID>18705566</PMID>
  </reference>
  <reference>
    <citation>Bagshaw SM, Bellomo R, Jacka MJ, Egi M, Hart GK, George C; ANZICS CORE Management Committee. The impact of early hypoglycemia and blood glucose variability on outcome in critical illness. Crit Care. 2009;13(3):R91. doi: 10.1186/cc7921. Epub 2009 Jun 17.</citation>
    <PMID>19534781</PMID>
  </reference>
  <reference>
    <citation>Egi M, Bellomo R, Reade MC. Is reducing variability of blood glucose the real but hidden target of intensive insulin therapy? Crit Care. 2009;13(2):302. doi: 10.1186/cc7755. Epub 2009 Apr 6.</citation>
    <PMID>19435472</PMID>
  </reference>
  <reference>
    <citation>Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D, Tchetche D, Carrié D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P, Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J, Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau X, Ohlmann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F, Bertrand B, Van Belle E, Laskar M; FRANCE 2 Investigators. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012 May 3;366(18):1705-15. doi: 10.1056/NEJMoa1114705.</citation>
    <PMID>22551129</PMID>
  </reference>
  <reference>
    <citation>Eltchaninoff H, Prat A, Gilard M, Leguerrier A, Blanchard D, Fournial G, Iung B, Donzeau-Gouge P, Tribouilloy C, Debrux JL, Pavie A, Gueret P; FRANCE Registry Investigators. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J. 2011 Jan;32(2):191-7. doi: 10.1093/eurheartj/ehq261. Epub 2010 Sep 15.</citation>
    <PMID>20843959</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Besancon</investigator_affiliation>
    <investigator_full_name>Guillaume BESCH</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>aortic valve replacement</keyword>
  <keyword>percutaneous valve</keyword>
  <keyword>blood glucose variability</keyword>
  <keyword>TAVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

